Patterned repetitive TMS over the supplementary motor area for Parkinson's bradykinesia
Official title: Enhancing rTMS Effects Through a State-Dependent Approach - An Intervention for Bradykinesia in Parkinson's Disease
Run by Danish Research Centre for Magnetic Resonance · NCT07397377 · Data updated 2026-11-12
This trial will try patterned repetitive transcranial magnetic stimulation over the supplementary motor area to reduce slowness of movement in people with Parkinson's disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 27 (estimated) |
| Sponsor | Danish Research Centre for Magnetic Resonance Academic / other |
| Locations | 1 site (Hvidovre) |
| Status | Recruiting |
| Started | December 16, 2025 |
| Main results expected | May 1, 2027 |
| Study ends | May 1, 2027 |
| Registry record updated | February 9, 2026 |
| Trial ID | NCT07397377 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with clinically established or probable Parkinson's disease, on stable antiparkinsonian medication, able to undergo MRI and TMS, and willing to give informed consent are ideal candidates.
✕Probably not a fit
People with contraindications to TMS or MRI, a history or family risk of seizures, current use of excluded psychiatric or GABAergic medications, or who are pregnant are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial delivers patterned repetitive transcranial magnetic stimulation (prTMS) targeted to the supplementary motor area (SMA) and compares active stimulation with a sham procedure. Participants with clinically established or probable Parkinson's disease who are stable on antiparkinsonian medication will receive sessions of either active or sham prTMS, with motor function measured before and after the intervention. The study excludes people with epilepsy risk, certain psychiatric medications, MRI or TMS contraindications, and pregnant participants. Results will focus on changes in bradykinesia severity and related motor measures.
Why it matters
Potential benefit: If successful, this could reduce bradykinesia symptoms with a noninvasive treatment and potentially delay or reduce the need for invasive options like deep brain stimulation.
How similar studies have gone: Noninvasive TMS approaches have shown promise in small studies for motor symptoms, but patterned rTMS over the SMA remains relatively novel and not yet widely proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Above 18 years of age. Clinically established or probable Parkinson's Disease (PD), according to the Movement Disorder Society. Clinical Diagnostic Criteria for PD. Stable antiparkinsonian medicine for at least four weeks. Signed informed consent. Exclusion Criteria: Psychiatric disorders. Current use of antipsychotic medication, Donepezil, or GABAergic agents (e.g., pregabalin, gabapentin). Frequent benzodiazepine or opioid use defined as more than once per week on a regular basis. History of neurological disease other than PD. Past or present mental illness. History of epilepsy/conditions associated with increased risk of seizure induction through transcranial magnetic stimulation (TMS). Close relatives suffering from epilepsy/conditions associated with increased risk of seizures. Contraindications for magnetic resonance imaging (MRI) Contraindications for TMS Female participants of childbearing age must not be pregnant and must use contraception during the trial. Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation in the study.
Where it's running
-
Drcmr
Hvidovre, Denmark Recruiting
Study contacts
- Study coordinator: Ann-Charlot Rughaven, M.Sc.
- Email: ann-charlot.rughaven@regionh.dk
- Phone: +4521123531
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.